Cocrystal Pharma Announces Plans to Advance Coronavirus Program
March 06 2020 - 4:01PM
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or
the “Company”), a clinical stage biotechnology company
discovering and developing novel antiviral therapeutics,
today announced it has initiated its Coronavirus program.
“Following our acquisition of patent rights and
know-how from KSURF and our recently completed financing, we are
aggressively pursuing the development of novel antiviral compounds
for the treatment of Coronavirus infections using our established
proprietary drug discovery platform. Given the global threat of
COVID1-9, our primary goal is to advance our Coronavirus program
into preclinical development. We will seek opportunities for
collaborations as we advance our programs,” stated Dr. Gary Wilcox,
Chairman and Chief Executive Officer of Cocrystal.
Cocrystal recently entered into a license
agreement with KSURF to further develop certain proprietary
broad-spectrum antiviral compounds for humans to treat Norovirus
and Coronavirus infections. Cocrystal intends to pursue research
and development of theses antiviral compounds, including
preclinical and clinical development. This license advances the
Company's antiviral programs significantly by providing potent
compounds for further development.
For additional information about the Company’s
development pipeline, please visit www.cocrystalpharma.com.
About Cocrystal Pharma,
Inc.
Cocrystal Pharma, Inc. is a clinical stage
biotechnology company discovering and developing novel antiviral
therapeutics that target influenza viruses, hepatitis C viruses,
coronaviruses and noroviruses. Cocrystal employs unique
structure-based technologies and Nobel Prize winning expertise to
create first- and best-in-class antiviral drugs. For further
information about Cocrystal, please visit
www.cocrystalpharma.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements related to our Coronavirus
program and other statements that are not historical fact. We have
based these forward-looking statements largely on our current
expectations and projections about future events. Some or all of
the events anticipated by these forward-looking statements may not
occur. Important factors that could cause actual results to differ
from those in the forward-looking statements include, but are not
limited to, risks relating to intense global competition focused on
the Coronavirus, the results of our research using our proprietary
technology, the availability of products manufactured by third
parties, the future results of preclinical and clinical studies,
general risks arising from clinical trials, receipt of regulatory
approvals, and our ability to find and enter into agreements with
suitable collaboration partners, Further information on our risk
factors is contained in our filings with the SEC, including our
Prospectus Supplements dated January 29, 2020 and February 27, 2020
and our Annual Report on Form 10-K for the year ended December 31,
2018 and our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2019. Any forward-looking statement made by us herein
speaks only as of the date on which it is made. Factors or events
that could cause our actual results to differ may emerge from time
to time, and it is not possible for us to predict all of them. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by law.
Investor and Media Contact:JTC
Team, LLC(833) 475-8247COCP@jtcir.com
###
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024